Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase I Trial of Daily Lenalidomide (CC-5013, Revlimid™) and Docetaxel Given Every Three Weeks in Patients With Advanced Solid Tumors
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with docetaxel may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide when given together with docetaxel in treating patients with advanced solid tumors.
研究概览
详细说明
OBJECTIVES:
Primary
- Determine the dose-limiting toxicity and maximum tolerated dose of lenalidomide when given in combination with docetaxel in patients with advanced solid tumors.
Secondary
- Determine the safety of this regimen in these patients.
- Determine the objective tumor response in patients treated with this regimen.
- Determine the time to progression in patients treated with this regimen.
OUTLINE: This is a multicenter, dose-escalation study of lenalidomide.
Patients receive oral lenalidomide on days 1-14 and docetaxel IV over 1 hour on day 1. Courses repeat every 21 days until disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of lenalidomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Ohio
-
Cleveland、Ohio、美国、44106-5065
- Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
Histologically confirmed solid tumor
- Advanced disease
- Refractory to standard therapy OR no standard therapy exists
- Measurable or evaluable disease
No active brain metastases
- Previously treated (e.g., surgery or radiotherapy) brain metastases are allowed provided they are currently asymptomatic and inactive by CT scan or MRI
PATIENT CHARACTERISTICS:
Performance status
- ECOG 0-2
Life expectancy
- At least 4 months
Hematopoietic
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 8 g/dL
Hepatic
- Bilirubin normal
Meets 1 of the following criteria:
- Alkaline phosphatase (AP) normal AND AST or ALT ≤ 5 times upper limit of normal (ULN)
- AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN
- AP ≤ 5 times ULN AND AST or ALT normal
Renal
- Creatinine ≤ 2 mg/dL
Cardiovascular
- No New York Heart Association class III or IV heart disease
Immunologic
- No prior desquamating rash or ≥ grade 2 allergic reaction while receiving thalidomide
- No history of hypersensitivity to docetaxel or other drugs formulated in polysorbate 80
- No history of allergic reaction to compounds of similar chemical or biologic composition to study drugs
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other uncontrolled illness or other condition that would preclude study compliance
- No peripheral neuropathy ≥ grade 2
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No concurrent hematopoietic growth factors during course 1 of study treatment
- No concurrent immunotherapy
Chemotherapy
At least 6 weeks since prior mitomycin or nitrosoureas
- No more than 2 prior courses of mitomycin
- No other concurrent chemotherapy
Radiotherapy
- No prior pelvic radiotherapy
Other
- At least 4 weeks since prior anticancer therapy
- No concurrent warfarin for anticoagulation (heparin is allowed)
- Recovered from all prior treatment
- No other concurrent anticancer therapy except bisphosphonates
- No other concurrent investigational agents
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Maximum tolerated dose
大体时间:measured at end of phase I
|
measured at end of phase I
|
Dose-limiting toxicity
大体时间:measured after every course
|
measured after every course
|
次要结果测量
结果测量 |
大体时间 |
---|---|
Disease response
大体时间:measured after every 2 courses
|
measured after every 2 courses
|
合作者和调查者
调查人员
- 学习椅:Matthew M. Cooney, MD、Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.